eXoZymes

CEO of @messaginglab, @karlschmieder: "The scale-up problem in industrial biology isn't an engineering problem. Often, it's a biology problem. Cells are unpredictable by nature but eXoZymes eliminates that variable. When your chemistry runs outside the cell, you can engineer it like a real industrial process." Full 'Grow Everything' podcast episode with @eXoZymes CCO, Damien @Perriman, available as both video and audio here: na2.hubs.ly/H050-ct0 #exozymes #cellfree #biomanufacturing $EXOZ

eXoZymes (@eXoZymes) (Nasdaq: EXOZ) CEO Michael Heltzen was featured on Session 20 of the GeneCoda podcast Executive Insights for Life Sciences Innovators, in an episode titled “AI-enabled cell-free biomanufacturing and the future of enzyme engineering,” streamed live on YouTube on April 17. eXoZymes is a B2i Digital (@b2idigital) Featured Company. See their full profile at b2idigital.com/exozymes-1. In the conversation, Heltzen discusses the company’s thesis that producing complex molecules outside living cells can enable greater control, scalability, and speed compared to traditional biologic manufacturing. The discussion also covers how AI is helping identify and optimize enzyme pathways, the strategic considerations involved in building a platform company in today’s capital environment, what differentiates cell-free systems from established synthetic biology approaches, and where cell-free biomanufacturing could create commercial impact across nutraceutical, pharmaceutical, and industrial markets. Watch or listen here: exozymes.com/blog/podcast-g… Separately, eXoZymes and Cayman Chemical were featured in a Springwise case study on how the two companies are rethinking chemical manufacturing. The piece focuses on eXoZymes’ work bringing enzyme pathways from biology into the world of chemistry, with Cayman Chemical helping to scale the approach. CCO Damien Perriman is featured in the article. See the eXoZymes summary: exozymes.com/blog/springwis… eXoZymes is a Los Angeles, California-based biotechnology company that has developed a biomanufacturing platform offering the tools and insights to design, engineer, control, and optimize nature’s own natural processes to produce highly valuable natural products via a commercially scalable, sustainable, and abundant alternative: exozymes. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. Learn more about eXoZymes Inc. at exozymes.com. For investor inquiries, visit exozymes.com/investor and learn about other B2i Digital Featured Companies at b2idigital.com/featured-compa…. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of b2idigital.com/disclaimer.

This weekend, @eXoZymes CEO, Michael @Heltzen, was interviewed by Don Alexander of GeneCoda for the 'Executive Insights for Life Sciences Innovator' podcast, under the headline: "AI-Enabled Cell-Free Biomanufacturing and the Future of Enzyme Engineering" Check out the full episode here: na2.hubs.ly/H04Z8M90 $EXOZ #exozymes #exozyme #enzymes #enzyme #cellfree #biomanufacturing

Engineering biology for real‑world scale. We’re pleased to welcome @exoZymes as a sponsor of Bio-Innovations Europe 2026, supporting the next generation of high‑performance biomanufacturing. 📍 The Hague 📅 10–11 June 2026 #BioInnovationsEurope #IndustrialBiotech #Bioeconomy

Case study from @Springwise featuring Damien @Perriman: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturing. @eXoZymes takes enzyme pathways from biology and brings them into the world of chemistry. @CaymanChemical is helping to scale this novel approach Full case study available here: na2.hubs.ly/H04Xthr0 $EXOZ

Here's the answer: exozymes.twentythree.com/video/12540258…

Did you hear @erumazeez's excellent question to @Perriman: "Okay, so if NCT were a superhero, what would its superpower be?" Hint: It's not your usual superhero... check out the answer in the video below! The entire podcast episode is definitely worth a listen if you care about where biotech - and biomanufacturing - are actually heading: exozymes.com/blog/grow-ever… $EXOZ #exozymes #exozyme #enzymes #enzyme #biomanufacturing #biotech #synbio

Come join the community lead @eXoZymes Investor Discord! 🧬 $EXOZ discord.gg/JyfWH5gS One of the best places to connect with other shareholders and stay up to date with all the company's developments

NCT, although very well known for its metabolic benefits, until now has not been able to be produced at scale and purity @CaseyMeansMD @hubermanlab @drmarkhyman @PeterAttiaMD

Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen In this episode, John Gagliano of @BPharmCatalyst sits down with Michael @Heltzen, CEO of @eXoZymes, to discuss the revolutionary move toward cell-free biomanufacturing. Discover how eXoZymes is using AI to bypass the limitations of living cells, engineering "super-enzymes" through brute-force evolution, and bringing high-purity natural compounds like NCT to the mass market. Full episode available here: na2.hubs.ly/H04RWNw0 $EXOZ #exozymes #exozyme #biomanufacturing

Grow Everything podcast: In this episode, Damien Perriman, CCO of @eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules. @Perriman states: “eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.” Full @messaginglab podcast episode available as both video and audio here: exozymes.com/blog/grow-ever… #exozymes #cellfree #biomanufacturing $EXOZ

From The @villagevoice: The Metabolic Engine - How Scientists Are Exploring a New Path Beyond GLP-1 Weight-Loss Drugs America’s weight-loss conversation has changed almost overnight. Prescription drugs once reserved for diabetes treatment are now household names, promising dramatic results on the scale. Many therapies currently available focus on reducing appetite or limiting calorie intake, which can certainly lead to weight loss. Yet those solutions often address the symptom rather than the deeper metabolic engine driving the condition. Interest is growing around strategies that target the body’s internal energy system itself. Instead of simply telling the body to eat less, researchers are investigating ways to improve how the body burns energy, processes fat, and maintains metabolic balance. That shift in thinking has opened the door to a small but intriguing molecule known as N-trans-Caffeoyltyramine, or NCT. Full story available here: na2.hubs.ly/H04N4_c0

@eXoZymes Inc. (Nasdaq: EXOZ) is pleased to participate in the Second Annual Centri Capital Conference, taking place Tuesday, April 14, 2026, at @Nasdaq MarketSite in New York City. The Centri Capital Conference is a @b2idigital Featured Conference. See more details at: b2idigital.com/centri-capital… eXoZymes Inc. (Nasdaq: EXOZ) is a biotechnology company that has developed a new way to produce chemicals without using living cells. The company's technology, called "exozymes," combines enzymes (proteins that speed up chemical reactions) with artificial intelligence to create a manufacturing platform that transforms biomass into chemicals, medicines, and fuels. Unlike traditional synthetic biology that relies on living cells, eXoZymes' cell-free approach operates more like industrial chemistry, avoiding the common problems that prevent biological manufacturing from reaching commercial scale. Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception. B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, Nikki Frazier, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors. The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: meetmax.com/sched/event_13… Learn more about eXoZymes Inc. at b2idigital.com/exozymes-1?hsL…. Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

CCO at @eXoZymes, Damien Perriman, interviewed at @Nasdaq around our NCT project: "We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine." #exozymes #exozyme #enzymes #enzyme #NCT #Nasdaq #ntranscaffeoyltyramine $EXOZ

I agree: The next generation of #biomanufacturing is cellfree (not cell based fermentation!), and as controversial that is to people in #synbio, I would like to extend an invitation to anyone that got a “project stuck in the cells complexity/unwillingness to be a chemical factory” and/or “had a hard time scaling up the production” to have a conversation about it all.

We're featured in this brilliant National Lab of the Rockies (formerly NREL) piece on cell-free biomanufacturing: “Cell-free biocatalysis for biomanufacturing - or cell-free biomanufacturing - essentially operates enzymatic cascades without the constraints of a living cell. This is a technology that could transform the bioenergy sector but also pharma and fine chemicals,” explained Yannick Bomble, an NLR principal scientist and an R&D leader in cell-free biomanufacturing. Full story from @NatLabRockies available here: na2.hubs.ly/H04FbxG0 #exozymes #biomanufacturing #exozyme #NREL #NLR $EXOZ

$EXOZ management to host conference call today at 5:30 PM Eastern: na2.hubs.ly/H04CgGV0 Michael @Heltzen, CEO of @eXoZymes (Nasdaq: EXOZ), states, “We’ve moved beyond our ‘big idea’ potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe sets us apart. We expect to see further value generating inflection points as programs like NCT and our cannabinoid initiatives continue to advance through commercialization milestones.” Full press release on the investor call here: na2.hubs.ly/H04Cmc40 #exozymes #exozyme #enzymes #enzyme #biomanufacturing

@eXoZymes Inc. has validated its cell-free biomanufacturing platform through a successful pilot-scale run with Cayman Chemical, producing over 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity. This milestone not only demonstrates the technology's scalability but also achieves a remarkable 99% feedstock conversion rate, paving the way for potential commercialization and collaboration opportunities in nutraceuticals and novel medicines. synbiobeta.com/read/successfu… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Mark your calendars: $EXOZ investor update: 4Q + full year 2025 - on - Tuesday, March 31, 2026 at 5:30 PM Eastern Time. CEO of @eXoZymes, Michael @Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. You can pre-register for the webinar HERE: na2.hubs.ly/H04vNGP0 #enzymes #exozymes #nutraceuticals #cellfree #exozyme #biosolution #biomanufacturing #enzyme

eXoZymes' Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical @CaymanChemical advanced the protocol from a 1-L setup to a 100-L pilot run, operating the reaction and analysis independently #biomanufacturing #AI #drugdevelopment hubs.li/Q047yD3s0